<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2043">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05582941</url>
  </required_header>
  <id_info>
    <org_study_id>IB 3799/18 PI</org_study_id>
    <nct_id>NCT05582941</nct_id>
  </id_info>
  <brief_title>Biomarkers of Cognitive Impairment in Blood Cells</brief_title>
  <acronym>COGNIMARK</acronym>
  <official_title>Use of Human Blood Cells for the Identification of Early Biomarkers of Cognitive Damage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of the Balearic Islands</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundació d'investigació Sanitària de les Illes Balears</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consorcio Centro de Investigación Biomédica en Red, M.P.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of the Balearic Islands</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to identify transcriptomic biomarkers in blood cells to diagnose&#xD;
      early cognitive impairment. This would allow preventing the development of severe&#xD;
      pathologies, such as Alzheimer Disease. In addition, this project will analyse the influence&#xD;
      of adiposity, obesity, nutritional habits and physical activity on cognition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood cells constitute a minimally invasive material, which is presented as potentially&#xD;
      suitable for addressing the identification of clinical diagnostic biomarkers. This study will&#xD;
      compare gene expression in blood cells of patients with various degrees of cognitive&#xD;
      alteration (mild cognitive impairment due to Alzheimer's disease and dementia due to&#xD;
      Alzheimer's Disease) compared to control individuals, to identify early biomarkers of&#xD;
      impaired cognition. The availability of non-invasive early biomarkers of cognitive&#xD;
      dysfunction is highly relevant in the field of public health, from the point of view of being&#xD;
      able to prevent or delay the onset and/or progression of dementia and other cognitive&#xD;
      disorders. In addition, it is intended to establish the association between the biomarkers&#xD;
      identified with nutritional imbalances and increased adiposity/obesity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2022</start_date>
  <completion_date type="Anticipated">January 26, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 26, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of semiquantitative gene expression of blood cells between the three groups</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Gene expression analysis performed by real-time quantitative polymerase chain reaction (RT-qPCR). Percentage of semiquantitative gene expression between the groups: MCI vs Control, AD vs Control, and MCI vs AD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mini-Mental State Examination (MMSE), questionnaire (numerical scale)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Cognitive test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA), questionnaire (numerical scale)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Cognitive test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive Reserve Questionnaire (CRIq), questionnaire (numerical scale)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Cognitive test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body composition (fat mass)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Percentage of fat mass measured using a dual energy x-ray absorptiometry (DXA) scanner</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Height (cm)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Basic anthropometric parameter, measured in centimeters with a tape-measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (kg)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Basic anthropometric parameter, measured using a scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist-hip ratio (numerical ratio)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Basic anthropometric parameter. Waist circumference (cm) and hip circumference (cm) will be combined to report waist-hip ratio (waist(cm)/hip(cm))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (mm Hg)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Basic anthropometric parameter, measured in millimeters of mercury with a blood pressure monitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI) (kg/m2)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Basic anthropometric parameter. Weight and height will be combined to report BMI in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete blood count test (numbers of cells/mcL)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Circulating parameter (from blood sample). It will be measured: red blood cells, white blood cells (neutrophils, lymphocytes, monocytes, eosinophils, basophils) and platelets. All of them measured in numbers of cells/mcL by a complete blood count test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose (mg/dL)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Circulating parameter (from blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides (TG, mg/dL)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Circulating parameter (from blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol (mg/dL)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Circulating parameter (from blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-density lipoprotein cholesterol (HDL-C,mg/dL)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Circulating parameter (from blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low-density lipoprotein cholesterol (LDL-C, mg/dL)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Circulating parameter (from blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase (AST, U/L)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Circulating parameter (from blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase (ALT, U/L)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Circulating parameter (from blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-glutamyl transpeptidase (GGT, U/L)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Circulating parameter (from blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transpeptidase (GGT, U/L)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Circulating parameter (from blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP, mg/dL)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Circulating parameter (from blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein E (APOE, mg/dL)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Circulating parameter (from blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin (HbA1c, %)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Circulating parameter (from blood sample)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Test on nutritional habits, questionnaire (numerical scale)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Lifestyle test. Test on nutritional habits based on a 14-item Mediterranean diet questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Physical Activity Questionnaire, IPAQ (numerical scale)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Lifestyle test, specifically a physical activity test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STOP-BANG Sleep Apnea Questionnaire (numerical scale)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Lifestyle test, specifically a screening for obstructive sleep apnea in adults</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait Speed Test (m/s)</measure>
    <time_frame>Baseline point (all groups)</time_frame>
    <description>Gait speed is recorded on a 4 meter walkway with 2 meter non-instrumented walkway segments at each end to allow for acceleration and deceleration. Gait speed recorded is the average of the speed for the two trials</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Mild Cognitive Impairment Due to Alzheimer's Disease</condition>
  <condition>Dementia Due to Alzheimer's Disease (Disorder)</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>20 individuals with no cognitive alterations or any other pathology which could alter cognitive performance or blood cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Cognitive Impairment Due to Alzheimer's Disease: MCI group</arm_group_label>
    <description>20 individuals diagnosed with Mild Cognitive Impairment Due to Alzheimer's Disease with positive AD markers in cerebrospinal fluid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dementia due to Alzheimer Disease: AD group</arm_group_label>
    <description>20 individuals diagnosed with Dementia Due to Alzheimer Disease with positive AD markers in cerebrospinal fluid</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention will be performed.</intervention_name>
    <description>No intervention will be performed.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Dementia due to Alzheimer Disease: AD group</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment Due to Alzheimer's Disease: MCI group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for analysis of gene expression and general clinical parameters&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All of the participants are from Spain.&#xD;
&#xD;
          -  Control group: the majority are recruited from an Adult University (UOM, Universitat&#xD;
             Oberta per Majors, University of the Balearic Island).&#xD;
&#xD;
          -  Mild Cognitive Impairment and Alzheimer Disease groups: are recruited from the&#xD;
             University Hospital, Son Espases, Mallorca, Spain.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Control group&#xD;
&#xD;
             Inclusion criteria:&#xD;
&#xD;
               -  Age between 55-80 years&#xD;
&#xD;
               -  Absence of cognitive symptoms&#xD;
&#xD;
               -  Normal neuropsychological examination, (Clinical Dementia Rating, CDR = 0)&#xD;
&#xD;
             Exclusion criteria:&#xD;
&#xD;
               -  Any disease that could influence their cognitive performance or blood cell&#xD;
                  parameters.&#xD;
&#xD;
          2. Group with Mild Cognitive Impairment Due to Alzheimer's Disease (MCI group)&#xD;
&#xD;
             Inclusion criteria:&#xD;
&#xD;
               -  Age between 55-80 years&#xD;
&#xD;
               -  Established diagnosis of MCI&#xD;
&#xD;
               -  Cognitive deficit of 1.5 standard deviation in at least one of the&#xD;
                  neuropsychological tests performed, with no relevant functional repercussion&#xD;
                  (Functional Activities Questionnaire, FAQ&lt;7 and CDR≤0.5)&#xD;
&#xD;
          3. Group with Dementia Due to Alzheimer Disease (AD)&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Age between 55-80 years&#xD;
&#xD;
          -  Established diagnosis of Alzheimer's disease&#xD;
&#xD;
          -  CDR ≥ 0.5 and positive AD markers in cerebrospinal fluid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Oliver, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of the Balearic Islands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paula Oliver, Professor</last_name>
    <phone>+34-971172548</phone>
    <email>paula.oliver@uib.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carmen García</last_name>
    <phone>+34-971259506</phone>
    <email>carmen.garcia@uib.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of the Balearic Islands</name>
      <address>
        <city>Palma, Mallorca</city>
        <state>Balearic Islands</state>
        <zip>07122</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Oliver, Prof</last_name>
      <phone>+34-971172548</phone>
      <email>paula.oliver@uib.es</email>
    </contact>
    <contact_backup>
      <last_name>Carmen García</last_name>
      <phone>+34971259727</phone>
      <email>carmen.garcia@uib.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/pdf/10.1111/1541-4337.12363</url>
    <description>Review from the research group compiling all the research that supports the current study</description>
  </link>
  <link>
    <url>http://pubmed.ncbi.nlm.nih.gov/29566703/</url>
    <description>Article from the research group that supports the relation between normal-weight obesity in rodents and cognitive impairment in rats.</description>
  </link>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>July 28, 2022</study_first_submitted>
  <study_first_submitted_qc>October 13, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2022</study_first_posted>
  <last_update_submitted>October 19, 2022</last_update_submitted>
  <last_update_submitted_qc>October 19, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Blood cells</keyword>
  <keyword>Adiposity</keyword>
  <keyword>Nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Individual Participant Data (IPD) will be shared in due time if considered relevant for other research. With our current objectives, it is not considered necessary.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

